February 01, 2026

Dana-Farber Research News 02.01.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from December 16 - 31.

Dana-Farber

January 21, 2026

ADC Combination Outperforms Standard Treatment of Advanced Triple-Negative Breast Cancer

In patients with advanced triple negative breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus pembrolizumab led to durable responses and improved progression free survival compared to the current standard treatment, according to results of the ASCENT-04/KEYNOTE-D19 study, published today in the New England Journal of Medicine.

Dana-Farber

March 10, 2023

Four Leading UPMC/Pitt Scientists Receive Funding for Research in Breast Cancer

UMPC Hillman Cancer Center researchers receive significant funding from the Breast Cancer Research Foundation to support investigations aiming to improve cancer screening and enhance HER2 therapy.

The ASCO Post

February 10, 2021

Severity of Patients’ Symptoms May Be Underrecognized During and After Breast Radiotherapy

Physicians may commonly underrecognize radiation-associated symptoms and their severity compared with self-reports of patients with breast cancer, according to a large study comparing patient-­reporte...

The ASCO Post

January 25, 2023

SERENA-2 Trial: Camizestrant Improves Progression-Free Survival in Advanced Breast Cancer

The oral selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival, as compared with fulvestrant, in previously treated postmenopausal women with advanced breast canc...

The ASCO Post

February 06, 2023

WHO Launches New Roadmap on Breast Cancer

The World Health Organization (WHO) has released a new Global Breast Cancer Initiative Framework, providing a roadmap to attain targets to save 2.5 million lives from breast cancer by 2040. The new fr...

The ASCO Post

June 16, 2023

Study Evaluates Clinical Utility of Novel Liquid Biopsy-Breast Cancer Methylation Prototype Assay

A novel, automated liquid biopsy test—the Liquid Biopsy for Breast Cancer Methylation assay—may be effective at predicting early disease progression and potential survival outcomes in patients with me...

The ASCO Post

July 17, 2023

Regional Nodal Irradiation and Locoregional Recurrence in Patients With Favorable-Risk Node-Positive Breast Cancer

In a secondary analysis from the SWOG S1007 trial reported in JAMA Oncology, Reshma Jagsi, MD, DPhil, and colleagues found low rates of locoregional recurrence irrespective of the use of regional noda...

The ASCO Post

September 01, 2021

A New Era of Hope for Patients With Triple-Negative Breast Cancer

Triple-negative breast cancer is a particularly devastating subtype of breast cancer, as it is often diagnosed in young women and is associated with an exceptionally poor prognosis. The “triple-negati...

The ASCO Post